Neuphoria Therapeutics Inc.
NEUPNasdaqCIK 1191070HealthcareFiscal year ends Jun 30
Latest reported revenue, Q4 FY2025−$13.3kRevenue, Q4 FY2025, three months to 2025-06-30−$13.3k. XBRL concept
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-09-29, accession 0001193125-25-223338. Derived: 12-month figure less the 9-month figure.Report this figureThree months to Jun 30, 2025, from the 10-K filed Sep 29, 2025.Latest quarter: Q4 FY2026
Three months to Jun 30, 2026, against the same quarter a year earlier.
- Revenuenot reported (Revenue not reported)No year-earlier figure to compare
- Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
- Operating marginnot reported (Revenue not reported)No year-earlier figure to compare
- Net marginnot reported (Revenue not reported)No year-earlier figure to compare
- Diluted EPSnot reported (Diluted EPS not reported)No year-earlier figure to compare
- Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare
Last eight quarters
Full statements| Line item | Unit | Q1 FY20252024-09-30 | Q2 FY20252024-12-31 | Q3 FY20252025-03-31 | Q4 FY20252025-06-30 | Q1 FY20262025-09-30 | Q2 FY20262025-12-31 | Q3 FY20262026-03-31 | Q4 FY20262026-06-30 | Shape over the periods |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $m | not reported (Revenue not reported) | 0.7Revenue, Q2 FY2025, three months to 2024-12-31$662.7k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-17, accession 0001193125-26-054509.Report this figure | 15.0Revenue, Q3 FY2025, three months to 2025-03-31$15.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-15, accession 0001193125-26-225442.Report this figure | (0.0)Revenue, Q4 FY2025, three months to 2025-06-30−$13.3k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-09-29, accession 0001193125-25-223338. Derived: 12-month figure less the 9-month figure.Report this figure | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | |
| Operating margin | % | not reported (Revenue not reported) | (558.8%)Operating margin, Q2 FY2025, three months to 2024-12-31. operating income / revenueOperating income: −$3.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-17, accession 0001193125-26-054509.Revenue: $662.7k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-17, accession 0001193125-26-054509.Report this figure | 79.8%Operating margin, Q3 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $12.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001193125-26-225442.Revenue: $15.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-15, accession 0001193125-26-225442.Report this figure | 43981.7%Operating margin, Q4 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$5.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-09-18, accession 0001193125-26-395536. Derived: 12-month figure less the 9-month figure.Revenue: −$13.3k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-09-29, accession 0001193125-25-223338. Derived: 12-month figure less the 9-month figure.Report this figure | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Net margin | % | not reported (Revenue not reported) | (293.2%)Net margin, Q2 FY2025, three months to 2024-12-31. net income / revenueNet income: −$1.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-15, accession 0001193125-26-225442.Revenue: $662.7k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-17, accession 0001193125-26-054509.Report this figure | 75.1%Net margin, Q3 FY2025, three months to 2025-03-31. net income / revenueNet income: $11.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-15, accession 0001193125-26-225442.Revenue: $15.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-15, accession 0001193125-26-225442.Report this figure | 66960.6%Net margin, Q4 FY2025, three months to 2025-06-30. net income / revenueNet income: −$8.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-09-18, accession 0001193125-26-395536. Derived: 12-month figure less the 9-month figure.Revenue: −$13.3k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-09-29, accession 0001193125-25-223338. Derived: 12-month figure less the 9-month figure.Report this figure | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Diluted EPS | $ per share | (0.62)Diluted EPS, Q1 FY2025, three months to 2024-09-30−$0.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001193125-25-281579.Report this figure | (1.79)Diluted EPS, Q2 FY2025, three months to 2024-12-31−$1.79 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-17, accession 0001193125-26-054509.Report this figure | 6.55Diluted EPS, Q3 FY2025, three months to 2025-03-31$6.55 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001193125-26-225442.Report this figure | not reported (Diluted EPS not reported) | (4.41)Diluted EPS, Q1 FY2026, three months to 2025-09-30−$4.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001193125-25-281579.Report this figure | (0.77)Diluted EPS, Q2 FY2026, three months to 2025-12-31−$0.77 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-17, accession 0001193125-26-054509.Report this figure | (0.09)Diluted EPS, Q3 FY2026, three months to 2026-03-31−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001193125-26-225442.Report this figure | not reported (Diluted EPS not reported) | |
| Free cash flow | $m | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20222022-06-30 | FY20232023-06-30 | FY20242024-06-30 | FY20252025-06-30 | FY20262026-06-30 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $m | 0.3Revenue, FY2022, twelve months to 2022-06-30AUD 263.6k. XBRL concept ifrs-full:Revenue. 20-F filed 2023-10-18, accession 0000950170-23-053873.Report this figure | 0.0Revenue, FY2023, twelve months to 2023-06-30AUD 22.0k. XBRL concept ifrs-full:Revenue. 20-F filed 2023-10-18, accession 0000950170-23-053873.Report this figure | not reported (Revenue not reported) | 15.6Revenue, FY2025, twelve months to 2025-06-30$15.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-09-29, accession 0001193125-25-223338.Report this figure | 1.2Revenue, FY2026, twelve months to 2026-06-30$1.2m. XBRL concept us-gaap:Revenues. 10-K filed 2026-09-18, accession 0001193125-26-395536.Report this figure | |
| Gross margin | % | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | |
| Operating margin | % | not reported (Operating income not reported) | (99709.6%)Operating margin, FY2023, twelve months to 2023-06-30. operating income / revenueOperating income: −$22.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-09-30, accession 0001213900-24-082909.Revenue: AUD 22.0k. XBRL concept ifrs-full:Revenue. 20-F filed 2023-10-18, accession 0000950170-23-053873.Report this figure | not reported (Revenue not reported) | (7.2%)Operating margin, FY2025, twelve months to 2025-06-30. operating income / revenueOperating income: −$1.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-09-18, accession 0001193125-26-395536.Revenue: $15.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-09-29, accession 0001193125-25-223338.Report this figure | (1401.1%)Operating margin, FY2026, twelve months to 2026-06-30. operating income / revenueOperating income: −$16.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-09-18, accession 0001193125-26-395536.Revenue: $1.2m. XBRL concept us-gaap:Revenues. 10-K filed 2026-09-18, accession 0001193125-26-395536.Report this figure | |
| Net margin | % | 346.5%Net margin, FY2022, twelve months to 2022-06-30. net income / revenueNet income: AUD 913.4k. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2022-10-14, accession 0000950170-22-019563.Revenue: AUD 263.6k. XBRL concept ifrs-full:Revenue. 20-F filed 2023-10-18, accession 0000950170-23-053873.Report this figure | (96982.3%)Net margin, FY2023, twelve months to 2023-06-30. net income / revenueNet income: −$21.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-09-30, accession 0001213900-24-082909.Revenue: AUD 22.0k. XBRL concept ifrs-full:Revenue. 20-F filed 2023-10-18, accession 0000950170-23-053873.Report this figure | not reported (Revenue not reported) | (2.4%)Net margin, FY2025, twelve months to 2025-06-30. net income / revenueNet income: −$369.6k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-09-18, accession 0001193125-26-395536.Revenue: $15.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-09-29, accession 0001193125-25-223338.Report this figure | (1145.7%)Net margin, FY2026, twelve months to 2026-06-30. net income / revenueNet income: −$13.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-09-18, accession 0001193125-26-395536.Revenue: $1.2m. XBRL concept us-gaap:Revenues. 10-K filed 2026-09-18, accession 0001193125-26-395536.Report this figure | |
| Diluted EPS | $ per share | (0.02)Diluted EPS, FY2022, twelve months to 2022-06-30−AUD 0.02 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2023-10-18, accession 0000950170-23-053873.Report this figure | (0.02)Diluted EPS, FY2023, twelve months to 2023-06-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-09-30, accession 0001213900-24-082909.Report this figure | (18.62)Diluted EPS, FY2024, twelve months to 2024-06-30−$18.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-09-29, accession 0001193125-25-223338.Report this figure | (0.23)Diluted EPS, FY2025, twelve months to 2025-06-30−$0.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-09-18, accession 0001193125-26-395536.Report this figure | (3.06)Diluted EPS, FY2026, twelve months to 2026-06-30−$3.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-09-18, accession 0001193125-26-395536.Report this figure | |
| Free cash flow | $m | (21.8)Free cash flow, FY2022, twelve months to 2022-06-30. operating cash flow − capital expenditureOperating cash flow: −AUD 21.8m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2023-10-18, accession 0000950170-23-053873.Capital expenditure: AUD 1.5k. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2023-10-18, accession 0000950170-23-053873.Report this figure | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Dec 2024 to Nov 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 2026-06-30 | $3.8m | 875,328 | Unchanged | |
| AdvisorShares Investments LLC | 2026-06-30 | $1.1m | 252,909 | Added+97,542 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2026-06-30 | $758.1k | 173,488 | Added+74,972 | |
| Shay Capital LLC | 2026-06-30 | $680.9k | 155,822 | Added+4,812 | |
| Balyasny Asset Management L.P. | 2026-06-30 | $621.5k | 142,228 | Added+45 | |
| CITADEL ADVISORS LLC | 2026-06-30 | $317.1k | 72,559 | Added+53,228 | |
| GEODE CAPITAL MANAGEMENT, LLC | 2026-06-30 | $216.4k | 49,516 | Reduced−2,491 | |
| Ikarian Capital, LLC | 2026-06-30 | $207.3k | 47,443 | Unchanged | |
| VANGUARD FIDUCIARY TRUST CO | 2026-06-30 | $147.7k | 33,806 | Added+217 | |
| ADAR1 Capital Management, LLC | 2026-06-30 | $131.1k | 30,000 | Unchanged |
Recent filings
All 219 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2308:00 ET | 8-K | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 9.01 Financial statements and exhibits | 0001213900-26-111863 |
| 2026-09-1820:33 ET | DEF 14A | Proxy statementPeriod 2026-11-02 | 0001140361-26-037139 |
| 2026-09-1820:10 ET | 10-K | Annual reportPeriod 2026-06-30 | 0001193125-26-395536 |
| 2026-07-2422:37 ET | 8-K | 1.01 Entry into a material agreement; 5.01 Change in control; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-081052 |
| 2026-05-2620:15 ET | 8-K | 8.01 Other events | 0001213900-26-061028 |
| 2026-05-1512:33 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-225442 |
| 2026-02-1720:57 ET | 10-Q | Quarterly reportPeriod 2025-12-31 | 0001193125-26-054509 |
| 2026-01-0822:48 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-002245 |
| 2025-12-2921:33 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000905148-25-004490 |
| 2025-12-1821:15 ET | 8-K | 3.01 Delisting notice | 0001213900-25-123289 |
Latest annual report
Form 10-K for the fiscal year ended Jun 30, 2026Filed Sep 18, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 1191070
- Tickers
- NEUP
- Exchange
- Nasdaq
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- Jun 30
- Incorporated in
- C3
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Former names
- BIONOMICS LIMITED/FI (to 2024-12-23)
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:35 ET. Listed shows no prices and gives no investment advice.